Latest / Powering the Future Within / Episode 19: "Investing in the Brain" with Mudit Jain of Treo Ventures and NuXcel
Transcript
- speaker-0: Welcome to Powering the Future Within, the podcast where we explore the breakthroughs shaping the future of MedTech. I'm Umar Bachnight, CEO of ResidentLink Medical. Each episode, we speak with a leader who is driving the next wave of medical innovation, advancing technologies that are smarter, less invasive, and more connected than ever before. This is where the future of health takes shape. Let's dive in. Today I'm delighted to be joined by Mudit Jane. Mudit has built an extraordinary career at the intersection of engineering, life sciences, venture capital, and company creation. He began as an electrical engineer before earning a PhD in biomedical engineering with a focus on cardiac electrophysiology. And later, he received an MBA from Wharton. That created a rare blend of technical depth, scientific expertise, and business leadership. Today, Moodit is the founder of New Excel and the founding general partner of Trio Ventures, where he is focusing on creating and investing in companies at the intersection of biology, deep technology, and health economics. Throughout his career, he has helped launch and scale companies tackling some of healthcare's most complex challenges. Always with an eye towards translating breakthrough science into technologies that improve patients' lives. What I find especially compelling about Mood's perspective is that he's seen innovation from nearly every angle as an engineer, as an in scientist, as a company builder, and as an investor. That combination gives him a unique lens on what separates promising ideas from transformative companies. In today's conversation, We'll talk about the experiences that shaped his journey, how he evaluates opportunities at the frontier of MedTech, what he's learned from founding and investing in companies, and where he sees the greatest opportunities for the next generation of healthcare innovation. Woodit, welcome to Powering the Future Within. speaker-1: Thanks, Amari, for having me on your podcast. A pleasure to be for talking to a fellow guidance Allah. speaker-0: Yes, fellow guidance alum. It feels as though so many careers started with with guidance ⁓ and that that led to be formative aspects. So was that would you describe mo ⁓ would you describe guidance as one of the more formative experiences that that you had? speaker-1: Definitely one of the first experiences in Met Tech that I had. speaker-0: Yeah. But but before that, your career started in electrical engineering and you transitioned then into cardiac electrophysiology and then venture capital and now ⁓ company creation through Trio and New Excel. ⁓ I'm curious, if you look back, was there always a common thread connecting those chapters, or does that only seem obvious in hindsight? speaker-1: You know, looking back, the path seems obvious, but when you're living it, you're simply making the best decision you can with the information you have at that point in time. So the story actually started in high school. In India where I grew up, the education system required us, at fourteen or fifteen, to choose a track that would determine whether you pursue engineering or medicine. And it was a difficult choice because my heart was medicine. But engineering was a family path. My dad was an electrical engineer, and he had to choose one. And after a lot of deliberation, I decided to go through the engineering route and chose electrical engineering. Ironically, that design that decision eventually brought me back to medicine. During my PhD, I applied electrical engineering to cardiac EP, and I discovered this incredible intersection between engineering and human biology. So looking back, that's been a common thread throughout my career, from cardiac EP to Neuromod, venture investing and building companies through New Excel. But you know, I really didn't have a master plan. I just kept following problems that fascinated me. It's only in hindsight when I look back that the connection sort of became clear. speaker-0: Yeah, and the connections are are incredibly powerful. So when you were studying electrical engineering and then you decided you were going to go down that path, what first made you realize that some of the most interesting electrical systems were the ones that aren't man made but are biological? speaker-1: Yeah. So, you know, the interesting thing is I I didn't discover biomedical engineering through a textbook or a planned career path. It really started with a conversation. My college sweetheart, who's now my wife, was also my an electrical engineering student in my class. At that time growing up in India, my view of electrical engineering was focused mostly on traditional industries. I didn't realize there was this entire field where engineering could be applied to medicine. She, on the other hand, was really interested in exploring biomedical engineering as a possible path. And that introduced me to the idea that electrical engineering could be used to understand and treat human body. And immediately resonated with me because I'd always been interested in medicine. Ironically, she never pursued biomedical engineering and continued in technology, but I got turned on towards biomedical engineering and opened the door for me. That curiosity ultimately led me to medical devices. Things like pacemakers really fascinated me and eventually to a PhD in biomedical engineering. And when I got to Duke, I was very, very fortunate to work with Dr. Patrick Wolfe, one of the leading thinkers in cardiac EP. Under his mentorship, I became fascinated by the idea that you could take engineering principles and apply technology, chips, sensors, algorithms, electrical systems to something as complex as a human heart. And again, a duke being surrounded by brilliant physicians and engineers who could speak both languages made that intersection even more compelling. That was really the moment I realized that really the most interesting electrical systems aren't man-made, but it's what biology has already created. speaker-0: Right. And and so you've discovered that intersection so enlightening, so much happening during that period of time, as you mentioned in cardiac rhythm management in terms of the development and evolution of the pacemaker, and then the implantable cardioverter defibrillator, and then eventually cardiac rhythm ⁓ cardiac resynchronization therapy, CRT technologies. There was so much evolution happening at that point in time. And and you've had so much of a a strong academic background, you earned the PhD. What convinced you that you still needed an MBA? Were was it that you were trying to acquire new skills or were you intentionally changing the lens through which you were looking at healthcare? speaker-1: Yeah, so MBA truly came from a desire to widen the lens through which I could contribute. ⁓ you know, there is sometimes a tendency to put people into boxes based on the background, and someone with a PhD or deep technical background may be viewed primarily as a scientist or engineer, and that perception can unintentionally limit how others see their ability to contribute beyond the domain. I never saw technical depth. and commercial thinking as mutually exclusive. After my PhD while working industry, I found myself increasingly drawn to business development, interaction with entrepreneurs, company founders, and investors. So I really enjoyed that aspect of the business beyond just product development. So MBA was really a deliberate decision on my part to broaden that perspective. It wasn't about moving away from science and engineering. It was really about adding another dimension, so strategy, finance, company building, and so on. And looking back, that combination of perspectives has been critical in my career. The biggest opportunities in healthcare, as you know, often sit at the intersection of technology, medicine, business, and execution. And I wanted to be able to operate across those boundaries. speaker-0: Right. Yeah. No, I find that the most powerful professionals really understand those intersections and and those are prospectively where the most or the largest opportunities exist. And and I know your journey was heavily influenced by mentors along the way. I'm I'm curious, in your mentor conversation with technical leaders, is it often that you have this conversation about getting an MBA or getting, you know, formal business credentials? Is that A topic of conversation, is it still something you recommend to this day? speaker-1: You know, it depends on the individual. What MBA does is it kind of gives you a lot of information in a concise, short bullet form. So it's a very effective, quick way of gathering all that information. You can gather all that experience set at work. So it depends on where you are and what you want to do. It's not meant for everyone, but at the same time it can give you a pretty expedited framework to think through the business lens. And that's what it draw drew me to MBA. So it really comes down to an individual, their personalities and what their interests are and what they want to do. speaker-0: So it's not a magic wand. There's multiple ways you can get the experience, but it sounds like it worked really well for you. And you you've spent your career working on the body's electrical systems, first in cardiac electrophysiology, and now really across bioelectronic medicine and and more in neuromodulation. Are these fundamentally different fields or are they just different chapters in the same story? speaker-1: Yeah, so at eighty thousand feet, you know, I see them as chapters in the same story. Both cardiac AP and Neuromod are fundamentally about understanding and influencing body's electrical system. That's the basis. Technology foundations are remarkably similar. In fact they couldn't be much closer. You know, when you look at some of the core elements, implanted hardware, batteries, ASIC, leads, firmware, software. You're smiling because these are all the things that you probably experienced in CRM and the complex systems engineering. ⁓ the difference is that CRM has had decades of evolution, is an incredibly mature field. And we talked about some of those developments early on in the pacemaker, defibrillators, and then the CRT devices. Neuromod is still earlier in that journey, and we are continuing to see that technology and clinical understanding evolve. The science is also following a very similar path. You in cardiac EP we first had to learn how to map the heart. In fact, my PhD advisor, you know, he was known for mapping the heart, electrical mapping of the heart. And that's when we got an understanding of the electrical activity before we could actually precisely intervene with therapies. And Neuromod I think is going through a very similar evolution. It's all about learning how to map the nervous system. And understand how different circuits influence disease and function across multiple therapeutic areas. So there's really a strong connection between the fields. When you look at people, which I always think as the sort of binding element, many people in Neuromod come from CRS. They recognize the perils, the opportunity to use electrical systems to interact with biology. That's the basics of all this. While the different biology. speaker-0: Yeah. speaker-1: Cardiac technologies were mostly life sustaining and they were designed to maintain a critical function of the body. Neuromod is more focused on improving the quality of the life and the diseases we are addressing are incredibly complex. The brain, as you know, is arguably the most complex biological system that we know of, and we still have a lot to learn. But I believe over the next thirty to forty years, our understanding of the nervous system will continue to advance just as dramatically as our understanding of the heart has. speaker-0: You raise a really interesting point, which is the the basics of the technologies are very similar in principle, even in design and somewhat in terms of application. But a cornerstone of cardiac electrophysiology has really become these mapping systems that really allow us to understand on an individual level what the flow of electricity is essentially through the heart. Where there might be an aberration or abnormality and then how to address it. When you think about the nervous system, we don't have that same kind of diagnostic capability. Is that a field you see as a potential in terms of being able to map the the nervous system for an individual? Or how do you how do you envision that playing out? speaker-1: Yeah, and I and I think, you know, when you go and look back at the history of cardiac mapping, the core elements and sort of the basics of it were developed in the economic setting. That's not an endeavor that typically industry gets involved. It's basic science. And cardiac EP kind of evolved from there. Ultimately got industry got, you know, took over that and product productized that technology. We are very early on in the neuromod space in that in that mapping aspect. When you look at the academic work, there's a lot of mapping that's going on. There's a lot of mapping that's going on the peripheral side on the central nervous system and so forth in the brain. But brain is again super you know, it's probably a hundred times more complex than heart. And heart was very complex back then when we think about it. So I think we are still a long way to really get our arms around the brain and the signals and so forth. speaker-0: Yeah. Do you where do you think we are today in terms of ⁓ neuromodulation if you were to compare it to the journey of cardiac? Are we still in the very early stages, the early innings? Do you see some things that are are pretty advanced? I'm curious on your perspective on where you think we are on the journey. speaker-1: Yeah, so I mean when you think about CRM, the first pacemaker, you know, variable kind of nineteen fifty-seven. And then the first implantable device came out in nineteen sixty. And then when you think about the neuro aspect of things, spinal cord stimulator, the first device, kind of got implanted in nineteen sixty seven. It feels only a decade later, but when you think about the focus that went into the heart versus overall neuro, it was predominantly, I would say, cardiac over the last four years, fifty years. So cardiac as a result, and obviously life sustaining therapies and life sustaining technologies, they really took heart has always continued to be a big part of MedTech. So that continued to take, you know, Lion's share of the attention from science and technology perspective to understand it. New so science is slowly catching up on the brain. It's probably thirty, forty years behind compared to where we were with the cardiac. And then when you look on the scale from from a commercial setting, you know, CRM is somewhere in the order of 30 billion plus category. Neuromod, we are probably, you know, we st when I started in the space in around 2001, Neuromod was around $200 million business globally. Today it's close to 12 to 15 billion numbers, somewhere depending on different analysts. So it's kind of doubling every five years. But on a scale When you compare it to cardiac rhythm management, it's still a lot of catching up. And this is across multiple therapeutic areas. It's not just one single therapeutic area. So I think we are very early on in the development of overall use of Neuromod. And as we just understand more of peripheral, central nervous systems and get our arms around those, that's when that we'll see more technology being deployed across multiple therapeutic areas. So it's still very early on, I would say. speaker-0: Well we are seeing a significant amount of investment going into the space at almost unprecedented levels. I think there was a recent report. And for for if you look at it compared to cardiovascular, for example, the venture capital going into neuromodulation, brain computer interface, neurotech as a category was higher, I believe, than the amount of capital going in cardiovascular, depending upon the theory. Yeah, almost double. Almost double. Which is fascinating to think that you got there so early and now others are finally waking up to the opportunity. So what was it that made you realize that this parallel existed and made gave you the confidence and courage to jump in early? speaker-1: Yeah, you know, partially I'm kind of I'm single track mind minded. So I know something and I can see I can see patterns. And cardiac rhythm management or cardiac EP, as we said, you know, devices felt we have met most of the needs, not to say there's a lot of unmet needs still there. But when again you think about the brain, I think that's the next five decades. And when you think about every single organ ultimately is controlled by the brain. Isn't it? So i as our ability to map the neural circuits improves, devices become more so sophisticated, I believe that we will unlock many more applications. It's better biology, better engineering, better computational tools, and that is what is creating this enormous potential on the neural side. What I see with Neuromod is really the hope to offer to patients many of the conditions that you know, have not been addressed by drugs, or they have been poorly addressed by drugs, things like sleep apnea, migraine, pain, epilepsy, depression, they're not always immediately life-threatening, but they're profoundly disabling and dramatically affect quality of life. Many of these patients, as I mentioned, take medications and deal with the side effects with really no real relief from the symptoms or the disease. And this is where I think neuromod really provides typical immediate relief to these drug resistant, drug refractory patient populations. And it is just immensely rewarding to see the impact on those patients and their families. speaker-0: Yeah. Yeah. And we've talked about really two shifts which are very interesting parallels. One is the shift from cardiac kind of ⁓ an electrical system that exists almost in in a vacuum to a certain extent ⁓ to a certain extent versus the broader nervous system in the brain, which is much more open system, more difficult to really understand. So this shift from trying to adjust cardiac base issues to those that are really related to the nervous system and and really related to neurology. The other shift though is this idea of moving from devices that can treat mortality and sustain life to those that really boost quality of life. And I think both have very interesting economic ⁓ propositions around them to support them. But in some ways the neuromodulation case, if you can get people back to life, back to work, and that generally can affect the younger population, there's a very strong ⁓ there's a very strong case to make. that neuromodulation is really under sort of exposed or under treated or under addressed in ways that could unlock almost more economic benefit for communities. speaker-1: Absolutely. I mean, you know, I think Rob Binney from Sharotronics was on your podcast and he talked about how debilitating a disease chronic migraine is, or syndrome chronic migraine is. ⁓ you know, highly disabling, sort of top of the list of top five disabling diseases by WHO, World Health Organization. And most patients who are chronic migraine th they tend to be women, and they basically You know, they function certain few days a a month, but the rest of the time they're sitting in a dark room. Nothing works for them. ⁓ and I'm myself a episodic chronic migrainer. So the days I get chronic or the days I get migraine, I want my head chopped off. I want my head chopped off. I I have to work through it. It's it's it's almost a disease that is it's very difficult to fathom what a patient suffering from that goes through. Same thing with sleep apnea. You know, when I first invested in Inspire, CPEP works very well. You know, very effective therapy and every so the biggest question was will patients adopt a surgical therapy? When CPEP is in 98% effective therapy works very well, but poorly tolerated. The tolerance hasn't moved a bit since nineteen sixties or seventies. And I talked to a few physicians and I still remember this particular physician, he said, You know, do you you know, like when you fly overseas you get jet lag? I'm like, yeah. He says, Okay, first day what do you do? I'm like, kind of sleep through it. ⁓ second day what do you do? I'm like, yeah, try to get back to he says, okay. Now just imagine that you're doing everything possible to deal with that jet lag, but you have a year long jet lag. At that point in time, you'll go crazy and you'll do anything. So surgery is not a barrier. So I think when I think about neuromod, the space that I see the strongest case for neuromod, especially implantables, there's variables as well. For implantables is really where it's highly symptomatic disease. speaker-0: Yes. Highly symptomatic. And then this is another very interesting parallel that that you really kind of walked the line on, which is the compliance aspect. And and some of the wearable technologies like CPAP can really help treat conditions, but are very difficult for being tolerated or for patients to be compliant with. And implantables in many ways address that. They also sometimes can be more individualized. There's more data you can capture that's physiologic, et cetera. You've taken a pretty strong approach in saying that you are investing and focusing on implantables. And for for a lot of investors that's not been their pattern. So I'm curious on what's attracted you to the implantable space over maybe w focusing more on the wearable side. speaker-1: Yeah. So you know, one is I think you highlighted some of those. One is compliance, one is I think it's a direct therapy. And it depi to be honest, we have we have done variables. I've always done some variable, but very selectively. ⁓ IRhythm, which was a diagnostic patch for ⁓ you know, rhythm ⁓ monitoring, Noctrix, which was a variable for restless leg syndrome. So for very specific use case, variables make a lot of sense. And we had just invested in a company called Second Wave that is going after inflammatory disorders with a variable device using ultrasound stimulation. So we have a very strong bias towards implantables, but I think for certain disease cases, variables make sense. When it comes to a chronic disease, when it comes to the nerve target that has to be stimulated on a pretty regular basis. Those are the cases where implantables make more sense. And with implantable, you d you're directly on the nerve, so you know when you're stimulating, there's no collateral stimulation. So it has all those advantages besides compliance. It's a more effective therapy. Then it's always about assessing the the barrier associated with surgery versus the therapy efficacy. And I think as I said, if the disease is highly symptomatic, most patients are willing to make that compromise trade off. speaker-0: Absolutely. Yeah. Yeah. Yeah. So you've been a scientist, an engineer, an operator, a venture capitalist, board member, company builder. Is there a particular role that you felt taught you the most about what it really takes to build a transformative med tech company? speaker-1: Yeah, I mean, you know, these are all sort of additive experiences. With each of them contributing a different perspective. And they really become part of your overall armamentarium. The mindset and tools you develop to understand the opportunity, evaluate risk and reward, and more importantly, work with people across multiple functions and make better decisions. So I think that's been very helpful in dealing with the overall complexity of this industry, medical devices specifically. And it's a very similar approach we take at New Excel. We start by looking at clinical science literature to understand the problem. So this is a company formation part. And then, you know, once we understand that there's something that is signal, there's a signal in literature that something works. Then we start working towards identifying the right device solution to embody that therapy. And identify resources needed, build the right team, and then getting ready to take it through the FDA process and ultimately to commercial use. So I think it's a it's really combination of all those experiences that have been very useful for me. speaker-0: And you're also very active in Trio Ventures where you were a founding founding partner there. And so how do you think about the application for New Excel versus the applications for trio? speaker-1: Yeah. So, you know, at Trio we are obviously talking to many entrepreneurs. New Excel is more of captive. It's myself and other partner of mine, Lynn Elliott, whom you may know from Guident, used to run R and D there. so those are mostly ideas and thoughts that we kind of bring to bear. But when we are talking to outside, you know, entrepreneurs. not within the new Excel family, then we look at those opportunities. And, you know, we maintain a firewall. So anything that we invest with an outside entrepreneur, with another group, that is not something we'll do at New Excel. So that's those are the sort of firewalls we have to maintain. And it just comes down to there's so much to do. New Excel can only do so much. So there's there's a lot of work that is done outside and we want to participate in ⁓ you know helping those companies come to bear. speaker-0: there's spaces or places or concepts that you felt so strongly about and you realized that getting capital for them to get maybe through the product development phase would be so challenging that you just said new Excel's gotta go do this. Is that also part of it? We're seeing right now a really strong gap between being able to raise a series B, for example, versus a series C. And and we need more institutions to be able to fill in that gap. speaker-1: Yeah, so I think I won't say it's necessarily that, but it was it's a new Excel is sort of a unique model, and I'll ⁓ maybe I'll go a little bit into how that came together and what we look for there. So, you know, and when we started, we really were not sure how all these different pieces will come together at New Excel. What we did know, when I say we, it's myself and Lynn Elliott, that we wanted to combine three different perspectives. Technologist. Scientist and investor. Lynn and I had both spent time working with accelerators or incubators in a medtech space. And we were beginning to question whether that was always the most capital efficient way to create and bring new medical devices to market. We decided to turn that model around and turn it on its head and really go virtual. So when you think about incubators and accelerators, you always think of brick motor, few people in there and all that. COVID also helped, by the way. It forced us to be virtual, and then we realize that, you know, that's actually a pretty good model. We don't have to put a brick and mortar infrastructure around it because just turning the lights on for that kind of infrastructure requires its own capital. And we totally bypass that capital requirement. And that really helped us. So when we do a company, you know, we we are working virtually. There's as an accelerator, we burn probably hundred to two hundred bucks a month. Super feasible. Super We have done we have done four companies over the last six years. And on average, so if you think about the seed, so what we do is we identify a clinical need, we go through speaker-0: That's amazing. speaker-1: massive literature review to see what has worked in that disease state or not. And then once we are able to convince ourselves that there's really a strong signal that if you stimulate XYZ, ABC happens or you stimulate ABC, XYZ effect happens, then we start thinking about putting a device concept behind it. What may be the best device embodiment. And sheotronics again is a good example. Rob kind of walked you through that there. ⁓ So once we have the device concept, we start filing IP and then we you know again, this is where the investor mindset comes in. Because I know for me to go raise Series A, these are the questions I'll get asked. Yes. And I better have answered for those questions. So we will typically spend 300 to 500,000 of that seed money to answer those very specific questions. And we typically bring in a project lead who ultimately will be the CEO. taking over that company once series A is done. So there's a built in leadership that we are developing along the along as we are developing the concept towards a series A. speaker-0: Right. Okay. And so then Series A then represents sort of the graduation point, if you will. There's been very little capital deployed, but at the same time you've de risked it f in many ways from a technology perspective and then you can move on from there. speaker-1: Yeah. And our typical series A we have raised is around forty million dollars. And that series A allows us for all these companies to get to first in human experience because we know that's the major value inflecting milestone. speaker-0: Yeah. And then you have a little bit of clinical data, you've got your bench model that you can sort of repres replicate the physiologic mechanism of action. And and at that point you get through the series A and you can have a very meaningful series B that's now turning the corner and actually looking at a pivotal trial. speaker-1: Exactly. And fundraising is very time consuming, distracting, and not always very productive. So we try to kind of bypass doing small fundraises every six, eight, twelve months. And we typically look for three to four years of fundraising with really valuable milestones behind it. speaker-0: Seems like a really powerful model, especially 'cause that valley of death really seems to be occurring now between the series A and the and the series B. Absolutely. So your companies are getting a lot further. That's that's great. That's great. And and speaker-1: It's a modern as founders, but it's worth it. speaker-0: And then on the trio venture side, how are you spending your time there? speaker-1: Yeah, so you know, that's my primary job. So what I do at New Excel is kind of a weekend and you know, ⁓ after hours kind of stuff. there, you know, our focus is really on sort of the intersection of companies. Very big focus on Neuromod, because we do believe that Brain is the next frontier. But we are looking for companies where there's, you know, again the intersection of bi you mentioned that biology, technology, and health economics, how they come together. Because we believe that's the foundation on which successful healthcare companies are built. My partners Brad and Tracy Atreo, they're also strong believers of this philosophy. So when I look at our past successes, it has always been about serving large markets or big clinical needs. the focus on differentiated technology or solution. In our space it means building sophisticated devices that combine kind of like again, more like CRM devices, hardware, chips, sensors, algorithms, and maybe even some AI elements. It's funny, you know, we talk about AI obviously. Pacemakers had that going in the nineties. We are talking about prediction, prevention, all those things. And I think we're slowly trying to bring that all into the neural world. So these elements create a sort of a technology more and really sort of a barrier to entry. But ultimately, none of that matters if the solution does not fit into the healthcare system. It has to deliver meaningful value to the three Ps, patients, physicians, and payers. And that is where the health economics becomes critical. So even at the earliest stages of our companies, we start developing our health economics strategy and plans. When I look at some of the biggest successes that our team has had in the past, the companies we have backed, things like I talked about Inspire, iRhythm, NovoCure, Nevro, we see that pattern. These companies solved important clinical problems, built differentiated technology, and demonstrated enough economic value that the healthcare system embraced them. speaker-0: And on the flip side, and I mean you the great list of great companies and the list goes on. We could talk about Inspire, New Spera, C V R X, Shearatronics, Avival Med, IVACare, et cetera. Is there a common bottleneck that you find companies will run into as as they're trying to get to the market as a neuromodulation technology? speaker-1: Yeah, different phases, different bottlenecks, isn't it? ⁓ on the product development side, again, I won't go into the technical issues, you know, like vendors and so forth, and they're they're always a challenge in some ways. But one of the common themes, if you think about in any company, it's really ⁓ gaining access to exceptional talent. That is the biggest bottleneck. ⁓ doesn't mean we don't overcome it, but that is one of the biggest challenges. So let me start on the R D side. It's really tough to get experienced talent in the space. I mean, you can get the best mechanical engineer, best electrical engineer, and so forth, but they're not training the university education system how to put together class three implantable device. So they all have to come together, work in a regulatory product development environment while also being creative. Within the constraints of regulatory, clinical, commercial payer needs. So that's a very unique set of experiences these RD folks have. And it's very difficult to find them. ⁓ again, we have been very fortunate because of a long history in the space and the relationships that we have with people, trusted relationships we have had over the last decade or ⁓ three decades, that we are able to recruit them. But that's a common theme, and that translates over to You know, your market access team and then your commercial team, just people who understand class three active implantable devices. How to develop them, how to get through regulatory, and then how to commercialize them. speaker-0: Yes. So would you say that you're you're more of a believer in hiring best in class talent over co location? speaker-1: I'm a believer in both. I want the best of both. I want the best in class talent and having it co located. ⁓ you know, over COVID we all had to work through it, isn't it? And when we look back at our portfolio companies that perform better, it's usually companies that are co located. It's usually companies. There's just so much going on in a startup that being virtual does not help. We had to do it during COVID, but I think when you get to MedText out of Vault, most of our companies are co located. There are exceptions we make because sometimes you may not get access to that talent and you have to be flexible. But then we look for people who are very effective at working remotely and commuting. speaker-0: Yeah, yeah, it definitely takes that extra effort in terms of communication and engagement because a lot of times the biggest insights happen when you're engaging together physically. Right. I'm I'm curious on how you view platform technology. So as someone who's building a platform technology myself, I I often wonder when investors evaluated technology, what convinces them that they're looking at a high potential platform company versus just a decent product? speaker-1: Yeah. I mean what you're developing is very unique, isn't it? That is truly a platform technology applicable across multiple indications, multiple use cases and so forth. Most of the companies that I work with, they are focused on one therapeutic area generally. Isn't it? So I always say that a platform is worth something only if you can prove it in a use case first. Take a use case and prove it in there. Platform can also be perceived by a lot of us on the venture side as lack of focus. ⁓ So my advice generally as an investor, again, I may think differently a little bit as an entrepreneur, but as an investor, it's really to first convince and prove an investor about a use case that is relatively well quantified and well defined. Build your case for a platform from there. Don't go the other way around. speaker-0: Yeah, it sort of earned the right to become a platform by showing that you have an application first. Yeah. Yeah. And so you're a Duke basketball fan. I I believe your daughter even shares a birthday with Coach K. And we're talking about recruiting talented players. ⁓ Coach K built these championship teams. ⁓ you've built your career assembling founding teams and backing entrepreneurs. What else have you learned about the ingredients of a truly talented team? We talked about individuals, but how about on a on a team level? Yeah. speaker-1: Well, I'm excited that he brought up dear basketball. speaker-0: I'm a Michigan State basketball fan, so it didn't quite feel right. speaker-1: You're good too. You're you're you're you guys are pretty good. But I have to say Duke teams are unmatched, but our portfolio but our portfolio teams come close. They do come very close. you know the key ingredients of great teams are surprisingly the same. Whether you're sort of working or building a program like Duke or working on a transformative healthcare company. First and foremost, it is about having the right Leadership for the right stage of the company. You know, the skills needed to build technology and develop a product may be a little bit different than from what is needed for leading that pro program through clinical development, commercialization, and scaling. And very few, there are few, but there are very few leaders who excel across all phases. In some ways it's a little bit like you want to have strong players across every position. Which is very true. You want to have strong R and D, you want to have strong commercial and everything. But if you look at the CEOs, you know, like in case of Sheerotronic, Rob being an amazing commercial leader, who's kind of leading the company through clinical and hopefully commercial. The company was initially led by Lynn, Lynn Elliott, who was a very technically focused leader. So we moved from Lynn to transition from Lynn to Rob because of this evolution of the stage of the company. Second, I think you need people who are hungry. Success can sometimes reduce urgency. So finding leaders who still have that builder mentality is critical. Third, you need a culture of being capital efficient and scrapey. So living with limited resources. I worry that in part of some parts of Medtech, we are moving away from that startup mindset. But Craig companies are usually built By making smart decisions around capital efficiency with limited resources. And finally, you need clarity and alignment. So everybody needs to understand the mission, the priorities, and how their role contributes. At the end of the day, exceptional teams are, you know, they're not just throwing in a bunch of talented people. This is people with complementary skills, shared values, and a common purpose. That's what makes a real team successful. speaker-0: And you talk about the right leader for the right season. And I'm curious whether or not those conversations when the season's changing and you have a belief that the leader should change as well to match the season, are those difficult conversations? Have you found a formula that works for you in terms of how to engage in that conversation? speaker-1: Yeah, I I think it's it's always a tough it's always a tough discussion whenever there's change off leadership. You know, that's always very tough. ⁓ but I think when we start our companies, and I'll talk specifically about new Excel companies, we typically we actually focus on very strong technical leadership. Because the first four or five years of the company, that's what is focused on. But we want to have people who understand how to bring a product to market, who understand That they have to do certain things because of what the reimbursement requirements may be, and so forth. So these are people who actually do understand how to bring a product to market. They might have just not commercialized it. ⁓ and when we bring them, we bring in with the expectation that hey, you can prove yourself because some people scale up. I mean, I've worked with CEOs who were founders, engineers who have scaled really well in our industry. Reza Zadna is one example. Tim Herbert is another example, you know, engineers who went on to become very successful CEOs of very successful companies. So some people do scale up and some people don't. And I think it's again part of a selection process as we bring in those leaders. We want them to be self-aware. So they themselves start to pointing out that I'll take it up to this point and you start better start finding somebody to succeed me from here on. So it's actually been my experience in many cases that that's the conversation we have had, rather than, Hey, we need to look for a new leader. We have had those conversations too, but fortunately on the new Excel side, just because of the way we have selected has been this way. speaker-0: Right. And you've got that history of success. So it's you can also point to that pattern how it works. And generally for those that don't want to start to expand in different directions, they're much happier if they can remain sort of focused in in the domain that that really suits them and that they're excited about. Yeah. Yeah. So I'm curious then on your own leadership beliefs speaker-1: Well of speaker-0: Are there beliefs that have remained constant? Have there been beliefs on leadership that you've completely changed your mind about over over this journey? speaker-1: Yeah, I I think Kinna, as we just talked, they remain pretty constant and very simple. Great first and foremost, great teams win. Best outcomes come from bringing together talented people with complementary skills who want to work together and want to win together. Alignment. It is extremely critical. You know, this is MedTech success requires there's synchronization across scientists. Engineers, clinicians, investors, vendors, commercial teams, everybody has to understand the mission and how they contribute and that has to be very clear. I talked about scrappiness. Especially in early stage, resources are limit. Limited to be creative, and I'm talking regulatory environment, regulated environment and still being creative, resourceful, and making trade offs and being adapt. ⁓ I think I think what has really evolved over time in my appreciation that leadership needs to change with the stage of the company. The qualities needed and the skills needed evolve with the company. So principles really remain the same. Great people, teamwork, alignment, desire to win, and being scrappy. How you apply those principles evolves with the challenge in front of you. That's probably Evolution of my thinking at my speaker-0: Okay, great. And it it seem it's interesting because we all love to win, as you mentioned. About ten years ago, you ⁓ gave a very famous quote, I think, from Dennis Whateley. Failure is delay, not defeat, which is a really interesting perspective on failure. And I think about how you entered neuromodulation so early. And neuromodulation as a field has had remarkable breakthroughs, but also some setbacks. So did that philosophy ⁓ that you espoused ten years ago. Did that prove true? Dil failure is a delay, not defeat? speaker-1: Yeah, yeah, you know, f failure sucks. Failure truly sucks in the moment. There's no doubt about it. All of us would rather have every effort be successful, isn't it? But the reality is when you're pushing the boundaries of what's possible, failures are going to happen. Anything worth pursuing, especially in a field as you pointed out, is neuromod, which is very complex. It involves setbacks. We're dealing with biology. There's still many unknowns about the brain and the nervous system. And I would say that over time my perspective around failure has evolved to see it less as an endpoint, but more as information. So each setback has taught us something new about either biology, technology, the process, the problem, whatever we are trying to solve. And again, a great example in my personal sort of experience was chirotronics. So there was a lot of work done in the occipital nerve stimulation space to treat Chronic migraine. Now those trials did not deliver the outcomes we had hoped for, but they were incredibly valuable in advancing our understanding of the opportunity and the challenges. And those learnings from those trials really helped us design the sheetronics device to overcome some of the lead fracture, migration issues, and all those. So we came up with a purpose built device. Unfortunately or fortunately, we did not bear the expenses and the time of those failures. So it's not just learning from your failures, it's also what you learn from the failures in the space. But in some ways, these setbacks really help validate the importance of the problem and bring more innovation and attention to the space, as is happening in chronic migrant space. So, you know, the philosophy still holds true. Failure is not defeat, it is often Part of the path forward and understanding what speaker-0: So is that part of your screening then to look for, let's call it informative failures? speaker-1: very situational. I mean, you know, ⁓ it's I I won't say that's part of the to when you say screening, I'm assuming you mean for opportunity. Yeah. ⁓ what I won't call that as my primary screening parameter. I think what we're looking for in our screening is really an evidence somewhere that when you did something or you stimulated something, it caused an effect. And that effect was predictable. But somehow speaker-0: Exactly for opportunity. speaker-1: It all didn't work together because either there was lack of a specific device that could do it, or whatever the constraints. And then we tried to remove those constraints. speaker-0: Yeah, it's funny because a lot of times we think about innovation as being a flash of ⁓ insight. But what you're describing is more of a process that feels more systemic. So is it d do you believe that innovation can be systemized? speaker-1: So, you know, I wish I had those flashes of inspiration. People talk about it. People talk about it. And I wish I had those. But no, unfortunately not. My approach has always been less about waiting for a moment of inspiration because trust me, I'll be waiting a lot longer. But more about discipline, pattern recognition, and then execution. So and there's plenty of ri I can make research and example that speak to this kind of a pattern. ⁓ in innovation. ⁓ so new Excel, where we you know start new companies, our mantra is very simple. Frugality, focus, engineering rigor, and execution. And then rinse and repeat. So learn from that and rinse and repeat. And Lynn and I believe that the process and mindset of bringing innovative technologies to market, it could be systemized. But you know, we have only done it four times. So the scaling beyond what we have done. That still needs to be proved. speaker-0: Right. Well we'll we'll be watching closely as you go from four to forty. ⁓ and and then speaker-1: I wish. But thank you, I wish. speaker-0: So then we can circle back and really try it. It is it is. It is. But in reflection, you've spent now nearly three decades helping ideas become therapies and therapies become companies that improve patients' lives. When people look back on your career years from now, after you got to the forty, what do you hope they'll say was your greatest contribution? speaker-1: Yeah, it's tough. You know, it's funny you ask this because I really haven't given much thought to this. I'm more focused on today and tomorrow and working with these companies and you know, helping in whichever way I can to for them to be successful while we work on creating few more companies. But having said that, if I have to, I would hope that at the end of it people say that I help bring great people together. To build innovative medical technologies that advanced healthcare and made a meaningful difference in people's lives. The technologies and companies are important, but real impact comes from the teams that behind them. And it's the collective effort of everyone involved. So in years from now, if the people I've worked with say that we built great teams, tackled meaningful challenges, and contributed something lasting to medicine. That would be the greatest measure of success. And hopefully they say it was fun along the way. Because you know, building medical technologies, bringing them to market is not always fun. I always say we spend almost 95% of our time in the lows is for that occasional 5% highs that we live for. So you gotta have fun, but because it's really tough and In the end it should be both meaningful, impactful, and enjoyable. So that's what I hope the legacy is. speaker-0: It's such a great perspective. And you think about the individuals that we have the fortune of working with in the med tech industry, I think it's one of the reasons why we stay in it and why we're gravitating towards it is because of the people, the innovation and the impact. speaker-1: Absolutely. People first and foremost, it's a very unique set of people who work in this industry. speaker-0: Well, this has just been a tremendous conversation. Really enjoyed it. Really appreciate you coming on and sharing your experiences and your wisdom and your perspectives. speaker-1: Well Mari, thank you so much for having me over. I really enjoy the conversation. speaker-0: Absolutely, thank you. And thanks to all of you who are listening for joining us on Powering the Future Within today. If this conversation inspired you, follow the show and share it with your med tech community. I'm Omari Bachnight. Stay inspired and keep innovating.